Back to top

MTN-044/IPM 053/CCN019 was a Phase I study of a 90-day vaginal ring containing the antiretroviral drug dapivirine (200 mg) and the contraceptive hormone levonorgestrel (320 mg) to prevent both HIV and unintended pregnancy. The study was designed to assess the ring’s safety and drug levels in plasma and vaginal fluid among 25 women in the U.S. who used a single ring for 90 consecutive days or cyclically for 90 days (taking it out every 28 days for 2 days.) MTN-044/IPM 053/CCN019 also assessed the vaginal bleeding patterns associated with using the dual-purpose ring, either continuously or cyclically, as well as its acceptability.

Second early phase study of 90-day vaginal ring containing dapivirine and contraceptive shows promise as dual-purpose product for preventing both HIV and pregnancy
26-January-2021

First clinical trial of new dapivirine ring with both anti-HIV drug and contraceptive finds ring is well-tolerated with no safety concerns
24-October-2018

See Also
MTN-044/IPM 053/CCN019 Protocol

MTN-044/IPM 053/CCN019  Studies Page